APM Stock Summary and Trading Ideas (Aptorum Group Limited - Class A | NASDAQ:APM)

Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA).

Aptorum Group Limited - Class A trades on the NASDAQ stock market under the symbol APM.

As of July 31, 2026, APM stock price was flat at $0.70 with million shares trading.

APM has a beta of 2.74, meaning it tends to be more sensitive to market movements. APM has a correlation of 0.02 to the broad based SPY ETF.

APM has a market cap of $5.70 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, APM traded as high as $174.90 and as low as $.70.

APM has underperformed the market in the last year with a price return of -95.5% while the SPY ETF gained +19.4%. APM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -92.0% and -90.0%, respectively, while the SPY returned +4.2% and +0.5%, respectively.

APM support price is $.66 and resistance is $.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APM shares will trade within this expected range on the day.